Tarsus Pharmaceuticals, Inc. TARS Equity Method Investments
Equity Method Investments at other companies
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LongTermInvestments.
The official record: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tarsus Pharmaceuticals, Inc.'s equity method investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tarsus Pharmaceuticals, Inc.'s equity method investments?
- Tarsus Pharmaceuticals, Inc. (TARS) reported equity method investments of $3.87M in Q1 2026.
- How has Tarsus Pharmaceuticals, Inc.'s equity method investments changed year-over-year?
- Tarsus Pharmaceuticals, Inc.'s equity method investments increased by 29.0% year-over-year, from $3M to $3.87M.
- What does equity method investments mean?
- Investments in unconsolidated affiliates and joint ventures where the company has significant influence (typically 20-50% ownership), carried at proportional book value.